Compare · HUM vs ILMN
HUM vs ILMN
Side-by-side comparison of Humana Inc. (HUM) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HUM and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.23B, about 1.6x ILMN ($28.38B).
- HUM has been more active in the news (16 items in the past 4 weeks vs 8 for ILMN).
- Both have 25 recent analyst ratings on file.
- Company
- Humana Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $46.23B
- $28.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2000
- News (4w)
- 16
- 8
- Recent ratings
- 25
- 25
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest HUM
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)
- New insider Smith Paul John claimed no ownership of stock in the company (SEC Form 3)
- SEC Form 10-Q filed by Humana Inc.
Latest ILMN
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $123,000 worth of shares (615 units at $200.00), decreasing direct ownership by 3% to 20,338 units (SEC Form 4)
- SEC Form 10-Q filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
- SEC Form 3 filed by new insider Sullivan Michael C
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026